Society of Actuaries Research Project: *Introduction to Care Management Interventions and their Implications for Actuaries" May 14, 2008 **Agenda** Background to our research. Care Management Background. Review of the SOA research. 4. Questions? Background to our research • Traditionally, actuaries have been involved in healthcare *financial*, rather than clinical topics; Managed Care brings these two streams together: managing clinical activities and interventions for a financial outcome; Actuaries have begun to be more involved in the

care management/outcomes side of the business;
 Creates a need for actuaries to learn a new vocabulary and new techniques;

Creates *opportunity* for actuaries to demonstrate application of our skills in a new area.

• In the UK context, there will be a need for financial evaluation of different care management proposals

as the NHS reforms.

SOA Health Section called for proposals for projects in 2003. Awarded a project to research: "Evaluating the Results of Care Management Interventions: Comparative Analysis of Different Outcomes Measures" • Includes all Care Management Interventions although focus is on Disease Management. Total of 9 papers published, including trend paper in NAAJ. Rigorous peer-review process by Project Oversight Group. Additional chapters on Wellness added for book publication date Fall 2008. The 9 papers on Care Management: 1. Programs and Interventions - description of different types of care management interventions. 2. Actuarial Issues in Care Management. 3. A review of the Literature on Program Evaluations. 4. Understanding the Economics of Intervention programs 5. Measuring Disease Management Savings Outcomes. 6. An actuarial methodology for assessing Disease Management Outcomes. 7. A comparative analysis of Chronic and Non-chronic Member Cost Trends. 8. Practical application of different measurement methodologies. •Additional chapters on Wellness added for book – publication date **Acknowledgements** A large number of people contributed to this study: My co-authors: Henry Dove, Rob Bachler and Iver Juster. Highmark Inc. and Bill Cashion (Chief Actuary) for support of the analysis of their data. My colleague, Rebecca Owen, FSA, for analysis. The Project Oversight Group, for valuable comments and suggestions: Bryan Miller (Chairman), Margie Rosenberg, John Cookson, John Stark and Stacey Lampkin. Ronora Stryker and the SOA's Research Staff for their support and encouragement. And last but not least: the SOA Health Section and the Committee on Knowledge Extension Research for their financial support.

Background on Care Management Realization that a small % of members consume a large % of resources, AND • Role of the member: how do you encourage the Member to take more responsibility for own care? • Result is Care Management Interventions: programs that attempt to impose best-practice care pathways on providers and encourage PATIENT responsibility for their own care. **Background on Care Management** Interventions raise questions for actuaries: • Medical Management Departments are Expensive Resources • In health plans, they tend to be under different management structures than actuaries. · It is hard to measure their productivity and They tend to get a "bye" financially because they demonstrably "do good." **Background on Care Management** As the number and cost of intervention programs has risen, managements have begun to turn to their traditional financial advisors, the actuaries. Clinical metrics and evaluations are not part of the traditional actuarial syllabus. Change in focus: traditionally, actuaries have focused


© Copyright 2003. V.PS, Inc. All Rights Reserved.


on services (inpatient, outpatient, Rx, etc.). Focus is shifting to the member, the member's condition.

What is a reasonable cost for a member with a particular condition?

What is the increase in cost (trend) for member with a

particular condition?





| Heal | Health Risk Management - New View | | | | | | |
|---------------|---|--|--|--|--|--|--|
| | | | | | | | |
| SOLUCIA, INC. | The ultimate goal is to determine appropriate best- practice care for patients, depending on their conditions, developing a cost and transferring the risk deviation to insurers and medical managers. | | | | | | |
| | 12 | | | | | | |

| | | 1 |
|---------------|--|---|
| | | |
| | | |
| | | |
| . : | D : (II 004 D) | |
| INC. | Review of the SOA Research | |
| SOLUCIA, INC. | | |
| NOS | | |
| | | |
| | 13 | |
| | | |
| | | |
| | | |
| | | |
| 1: Int | roduction to Care Management Interventions. | |
| | | |
| | An introduction (for those not familiar with them) to | |
| | common types of care management programs. | |
| INC. | Pre-Authorization ReviewsConcurrent Review | |
| SIA, | Case ManagementDemand ManagementDisease Management | |
| SOLUCIA, INC. | Specialty Case Management Population Health Management | |
| S | • Wellness | |
| | | |
| | 14 | |
| | | |
| | | |
| | | |
| 2: Ac | tuarial Issues in Care Management | |
| | | |
| | Covers Measurement Principles, Study Design Issues | |
| | and Risk Factors. Addresses some issues of particular importance | |
| NC. | including Regression to the Mean, Risk Adjustment, the need for control and reconciliation of data, and | |
| SOLUCIA, INC. | operational issues. | |
| TOC | | |
| SC | | |
| | | |
| | 15 | |

| 2: Res | ults | of Interventions - F | inancial Jury is Out | |
|---|----------------|--|---|---|
| | | | | |
| | | | | |
| | | ndustry measures financia we are accustomed to (RC | | |
| | | Unrealistic Claims. | Tradisor dian propring. | |
| o. | | No GAAP for Financial Measu | ırement | |
| 르 | | Poor Reconciliation Controls | | |
| SOLUCIA, INC. | | Lack of understanding of, ar | | |
| $\stackrel{\circ}{\dashv}$ | | drivers of financial outcome | 5. | |
| SOI | • | "So how come, if you saved trend is continuing to increa | | |
| | | · · | | |
| | | | | |
| | | 16 | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | 1 |
| 3: Rev | /iew | of Published, Peer- | reviewed literature | |
| | | | | |
| | | | | |
| | Inte | ervention | # Studies | |
| | - | auth/Utilization Review | 9 | |
| ن | | current Review | 5 | |
| Ž | | e Management cialty Case Mgmt | 22 5 | |
| ₹ | | nand Management | 6 | |
| 9 | | ulation Management | 7 | |
| SOLUCIA, INC. | Dise TO | ease Management | 52 106 | |
| | 1101 | AL | 100 | |
| | | | | |
| | | 17 | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | 1 |
| 3: Re | view | of Published, Peer- | reviewed literature | |
| | | | | |
| | Total Numbe | | | |
| Intervention | of Studies | Major Findings | | |
| | | not subject to managed care show considerable opportunity management models changed; there is also evidence of incr | IR in the range of 10% to 15%. Recent International studies of data for utilization reduction. Early gains were not maintained as medical eased outpatient utilization due to inpatient UR. More recently these | |
| Preauthorization/ Utilization Review | 9 | reductions are in the range of 2% to 3%; savings are estimar of 4.60 based on reported intervention cost of \$16/member f Early gains due to Concurrent Review were not maintained a | ed at between \$25 and \$74 per member per year; we estimate ROI or this study. s medical practice patterns changed. Current evidence that | |
| Concurrent Review | 5 | Concurrent Review can reduce bed-days by 2% to 3%. One review). | study in a hospital setting showed ROI of 0.9 (savings < cost of | |
| Case Management | 22 | studies. ROIs in the range of 1.37 to 3.74 reported. | and program). Evidence exists of clinical improvement and i.e. A survey of CM financial outcomes for Diabetes found no valid | |
| Specialty Case Management | 5 | Evidence shows support for financial outcomes in mental he | | |
| Demand Manageme | ent 6 | between 1.37 to 3.86 to 1.0. | ssary physician and ER visits. Financial results indicate a return of ograms. One study reported an ROI of 5.0 to 1.0. Studies of | |
| Population Manage | ment 7 | programs to intervene within entire chronic condition sub-pop | ograms. One study reported an ROI of 5.0 to 1.0. Studies of ullations report measureable pmpm savings. pm savings, gross savings are estimated around \$1.45 pmpm. For | |

4: The Economics of Care Management DM Program Savings/Costs at different penetration levels Savings Savings Savings Savings Savings Savings Penetration (%)

What makes for a good savings estimate? | Reference Population: Outcomes measurement requires a reference population against which to evaluate the statistic(s) of interest. | Consistent Statistics: The outcome variable(s) should be measured identically in the reference and intervention populations. | Appropriate Measurement: Measure only what the intervention is designed to manage. | Exposure: The calculation of an actuarial statistic requires clear definition of the numerator and denominator = clear definitions of categories of members and time-periods.

20

5: Evaluating Savings Methodologies Evaluating different designs • Validity/rigor. • Familiarity. • Replicability (ability for the client to reproduce the results). • How the method is applied in practice. • Other issues and comments on the use of the design.

| | Method Type | Method | Validity/ Scientific Rigor | Famil- iarity | Replicability/ Auditability | Application | Evaluation of Methodology | Other issues |
|---|-----------------------|-------------------------------------|----------------------------------|-------------------|---|---|---|--|
| 1 | | Randomized control | High | High | Difficult to replicate and audit; need another randomized group. | Requires untouched, randomized, control group. Matric in the Intervention group is compared with the same matric in the control group, and the difference is assigned to the effect of the intervention. | "Gold Standard" method, although requires demonstration of equivalence. Need for incurred claims results in delays in evaluations. | Practical to implement and avoids adjustment issues, athough requires sufficient number of members. Viewed by health plans as difficult to implement and potentially unafficial. Randomization must occur at the population level if results are to be applied to the population. |
| 2 | thods | Temporal (Historical) control | High | High | Replicable and auditable | Requires population drawn according to identical rules from two periods. Metric from the period in terrevenion period is compared with the same matric from the Baseline period, adjusted with trend. Requires adjustment of the comparison population to be equivalent to the Intervention population. | Becoming the most widespread methodology in the industry. Need for incurried claims results in delays in evolustories. | Implicit assumption that regression to the mean is undershyldarbeled in the Baselne and Intervention protest, and then a boostered estimate is evoluble. |
| 3 | Centrol Group Methods | Geographic or product line controls | High Midium | High/ Moderate | Peplicable and auditable | Requires population drawn according to identical rules from two different groups (e.g., geographies). Matric from the innervention principal is compared with the same metric from the control, adjusted for all appropriate risk-factor differences. | Not widely used. | Sometimes difficult to adjust for the many risk factors that affect a population and its utilization (see Paper 2). |
| 4 | | "Patient as their own control" | Low | High | Replicable and auditable | Patients are identified pre- intervention and then followed post- intervention. Pre-intervention metric is compared with post-intervention metric. | Widely used, but regression to the mean issues are causing purchasers to re-evaluate (see Paper 2). | Theoretically possible to correct for the effect of regression, but no method has yet been developed to do so. |
| 5 | | Participant vs. Non-participant | Low | High | Replicable and auditable | Patients are invited to erroll in a program. Those who choose to erroll are subject to treatment; those who choose not to erroll form the control group. 22 | Widely used, but selection bias causes this methodology to be highly suspect. | Theoretically possible to correct for the effect of selection bias, the effect of a member's "effingness to change" is unnessurable. |

| | Method Type | Method | Validity/ Scientific Rigor | Famil- iarity | Replicability/ Auditability | Application | Evaluation of Methodology | Other issues |
|----|---------------------------|---|----------------------------------|------------------|--|---|---|--|
| 6 | oup Methods | Services Avoided (also called pre- intent/post- intent) | Moderate | High | May be difficult to replicate; auditable. | Record intent of different patients, track for a period of time to determine schall outcome, and assign a dollar value to the avoided event (adjusted for alternative treatment, if any). | Frequently used for small, highly-specialized programs (such as case management). | Two issues: participant bias (participants who are more likely to charge their minds seek information and support) and evaluation and recording of intent subjective. |
| 7 | Non-Control Group Methods | Clinical improvement methods | Moderate | Moderate | Difficult to replicate; difficult to assemble comparable clinical trial data. | Measure clinical improvement and eatimate financial savings using a model based on the difference in cost of well-managed and other patients. | Useful for small volume studies and when a result is required more quickly than data-based evaluations. | Requires review of the significant literature on clinical improvement, and a method for projecting financial from clinical improvement. To our knowledge there is no comparative study of results of clinical improvement and other methods. |
| | | Regression- | Unkroven | Low | Replicable and auditable | A regression line is fitted on the relationship between Year 1 and Year 2 costs in a population; Year 1 and Year 2 costs for the inferension group are then fitted and compared. A "aith" in the regression line indicates that the intervention has haid an effect. | | To be determined. |
| 2 | zatistical Methods | Time-series | Low | Low | Replicable and auditable | Extension of the Adjusted historical control methodology to multiple periods. | Not widely used in commercial evaluations. | The affect of changes in risk-factors (often reflected variations in Teind) is compounded over a period of years, making it very difficult to control this calculation. |
| 10 | | Benchmark | Low | Low | Replicable; difficult to assemble valid comparison data | Metric in the intervention group is compased with the same metric in another population. The difference is assigned to the effect of the interventation and savings are estimated accordingly. | Occasionally encountered in commercial associations. | Comparison populations are unlikely to be described in sufficient detail to determine their degree of comparability for the extent to which adjustment is required). |

| 6: An | actuarial methodology for DI | M savings evaluation | | | |
|---------------|---|----------------------|--|--|--|
| | | | | | |
| SOLUCIA, INC. | Most commonly-used in the induadjusted historical control metho Trend= actuarial concept. Other adjustments (plan design, age/sex) = actuarial concepts. Simple Example: | odoľogy. | | | |
| JCIA, | Estimated Savings due to reduced pmpy = Baseline Cost pmpy * Cost Trend \$\$(000 * 1.12 = \$0720) | | | | |
| | Minus: Actual Cost pmpy Equals: Reduced Cost pmpy | \$6,300 \$420 | | | |
| \mathcal{O} | Multiplied by: Actual member years in | \$420 | | | |
| 0) | Measurement Period | 20,000 | | | |
| | Equals: Estimated Savings | \$8,400,000 | | | |
| | 24 | | | | |

| | | 1 |
|---------------|---|-------------|
| 7: Tr | end Assumptions – Before we start | |
| | Because you are all actuaries, a trend question | |
| | Which of the following is True? A. Chronic Member Trend is HIGHER than Non-chronic | |
| A, INC. | Member Trend B. Chronic Member Trend is LOWER than Non-chronic Member Trend. | |
| SOLUCIA, INC. | C. Chronic and Non-chronic Trends are about the SAME. | |
| S | | |
| | 25 | |
| | | |
| | | |
| | | I |
| 7: [| Data/Methods | |
| | Calculated Chronic, Non-chronic and population trends | |
| | for 1999 through 2002. Ingenix data set – 1.5 million commercially insured | |
| INC. | members. Chronic members identified with: • Asthma | |
| SOLUCIA, INC. | COPD CHF Diabetes | |
| NOS | • CAD | |
| | | |
| | 26 | |
| | | |
| | | |
| | | |
| 7: T | rend Results | |
| | | |
| | Average 3-year trends* | |
| NC. | Chronic 5.6% Non-chronic 13.8% | |
| SOLUCIA, INC. | Population 16.0% | |
| 00708 | * Prospective chronic identification | |
| | | |
| | | |

| - | Year 1999 2000 2001 2002 | Chronic Member Months 463,196 701,398 845,883 990.646 | Chronic Prevalence 4.1% 6.0% 7.0% 8.6% | Chronic Cost PMPM \$ 745.87 \$ 746.42 \$ 820.27 \$ 879.71 | Chronic Cost Trend - 0.1% 9.9% 7.2% | Total Chronic Cost (\$'000) \$ 345,483 \$ 523,538 \$ 693,856 \$ 871,485 | Chronic Cost as % of Total 14.5% 18.3% 20.3% 23.1% | | | | |
|---|--------------------------------------|---|---|--|--|--|--|---|--|--|--|
| - | Year 1999 2000 2001 | Non-Chronic Member Months 10,956,779 11,067,274 11,241,633 10,591,169 | | Non-Chronic Cost PMPM \$ 186.26 \$ 211.41 \$ 242.83 \$ 274.44 | 5.6% Non- Chronic Cost Trend - 13.5% 14.9% 13.0% | Total Non- Chronic Cost (\$'000) \$2,040,836 \$2,339,693 \$2,729,790 \$2,906,654 | Non-Chronic Cost as % of Total 85.5% 81.7% 79.7% 76.9% | | | | |
| - | Year 1999 2000 2001 | Total Member Months 11,419,975 11,768,672 12,087,516 11,581,815 | | Total Cost PMPM \$ 288.96 \$ 243.29 \$ 283.24 \$ 326.21 | Total Cost <u>Trend</u> - 16.4% 16.4% 15.2% 16.0% | Total Cost (\$'000) \$2,386,319 \$2,863,231 \$3,423,646 \$3,778,138 | Less than 1/ | 2 | | | |

| 7: T | 7: Trend Results - Alternatives | | | | |
|---------------|---------------------------------|----------------|--|--|--|
| | | | | | |
| | Adjusted for high-cost | outliers | | | |
| | Average 3-year t | rends* | | | |
| SOLUCIA, INC. | Chronic Non-chronic | 4.9% 13.9% | | | |
| CIA | Population | 16.2% | | | |
| nTos | * Prospective chronic | identification | | | |
| | | 29 | | | |

| 7: Trend Results - Alternatives | | | | | | |
|---------------------------------|--|----------------|--|--|--|--|
| | | | | | | |
| | Adjusted for chronic service mix* | | | | | |
| INC. | Non-chronic, unadjusted Non-chronic, adjusted | 13.8% 13.2% | | | | |
| SOLUCIA, INC. | * Prospective chronic identification | | | | | |
| | 30 | | | | | |

| 7: Ch | ronic vs. Non-chronic trend with | |
|------------------|---|---|
| | pective classification | |
| | Chronic | |
| | Retrospective Prospective Year Mem Months Identification Identification | |
| | 1999 1,410,116 | |
| | 2002 1,317,536 16.3% 7.2% Three year annualized 16.3% 5.6% | |
| N N | Non-chronic Retrospective Prospective Year Mem Months Identification Identification | |
| Ă, | 1999 10,009,8301 17.8% 13.5% | |
| SOLUCIA, INC. | 2000 10,225,301 17.5% 13.5% 2001 10,649,644 17.0% 14.9% 2002 10,264,279 15.5% 13.0% Three year annualized 17.2% 13.8% | |
| SOI | TOTAL | - |
| | Retrospective Prospective Prospective | |
| | 2001 12,087,516 16.2% 16.4% 2002 11,581,815 15.3% 15.2% | |
| | Three year annualized 16.0% 31 16.0% | |
| | | |
| | | |
| | | |
| | | |
| | | • |
| | olication of Risk Adjustment (DxCG ective risk score) | |
| | | |
| | | |
| | Average 3-year trends* | |
| | Chronic 12.5% | |
| NC. | Non-chronic 11.9% | |
| SOLUCIA, INC. | | |
| 70, | * Prospective chronic identification | |
| 30L ¹ | | |
| 0, | | |
| | | |
| | 32 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 7: Cor | nclusions | |
| | | |
| | | |
| | Trend has a large potential impact on the results of an adjusted pre- post study. | |
| | adjusted pro- post study. | |
| S. | When chronic members are identified using a prospective methodology, neither the non-chronic nor prospective methodology. | |
| SOLUCIA, INC. | prospective methodology, neither the non-chronic nor population trend is particularly close to chronic population trend. In particular, the chronic trend is | |
| CIA | lower than either the non-chronic or population trend. | |
| OLU | The authors term this effect "Migration Bias". | |
| S | - The admits term this effect. Migration bias . | |
| | | |
| | | |

| 7: Co | onclusions | |
|---------------|---|---|
| | | |
| | Some obvious adjustments (for catastrophic claims and for differences in services) do not | |
| | affect the trend differences much. | |
| A, INC. | Using a retroactive identification algorithm, chronic, non-chronic and population trends are much closer. | |
| SOLUCIA, INC. | Adjusting PMPM claims for changes in risk-score also causes trends to be more comparable. | |
| | | |
| | 34 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 7: Cd | onclusions - Postscript | |
| | | |
| | | |
| | In a paper published subsequently, we demonstrate that equivalence requires adjustment – not only of | |
| | the trend calculation, but also of the intervention | |
| ပ | population. | |
| Z | We address ways to do this in a paper in the Journal | |
| Ä, | Disease Management which is reproduced in a forthcoming book. | - |
| SOLUCIA, INC. | | |
| | | |
| | | |
| | | |
| | 35 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 7: Co | onclusions for DM purchasers | |
| | | |
| | Trend matters a lot. | |
| | Total Matters a lot. | |
| NC. | In some circumstances, migration can result in the use of inappropriate trend which, in turn, can overstate the calculated savings. | |
| | Ask questions about how populations are identified | |
| SOLUCIA, INC. | and how trend is calculated. | |
| | | |
| | | |
| | | |
| | 36 | |

Partnered with Highmark, Inc. 2-1/2 million members covered by a DM program administered by Health Dialog, Inc. Focused mostly on 200,000-member Medicare Advantage (over-65) members. Study period 10/1/2001-9/30/2003.

8: Application to Health Plan DM Data

- Base-case (per Paper 6) plus 5 alternatives.
- Alternative 1: Cohort Study.
- Alternative 2: 3 different chronic identification algorithms.
- Alternative 3: Retrospective Identification of Chronic Members.
- Alternative 4: No continuous eligibility requirement.
- Alternative 5: Commercial HMO/POS population.

38

8: Alternative Scenarios

| Scenario Number | Scenario | Intervention Year 1 10/01 – 9/02 PMPM Savings | % change compared with Base- case | Intervention Year 2 10/02 – 9/03 PMPM Savings | % change compared with Base- case |
|--------------------|---|--|--|--|--|
| 0 | Base-case | \$41.54 | - | \$65.28 | - |
| 1. | Cohort | \$39.59 | (4.7%) | \$57.93 | (11.3%) |
| 2a. | Medical claims only identification | \$49.96 | 20.3% | \$77.16 | 18.2% |
| 2b. | Primary diagnosis only identification | \$52.22 | 25.7% | \$85.32 | 30.7% |
| 2c. | Hospital claims only identification | \$44.14 | 6.3% | \$57.93 | (11.7%) |
| 3. | Retrospective identification | (\$0.47) | (100.0%) | \$3.01 | (95.4%) |
| 4. | No continuous eligibility or "waiting period" requirement | \$64.57 | 55.4% | \$111.22 | 70.4% |
| 5. | Commercial HMO Product | \$35.12 | n/a | \$49.88 | n/a |

39

8: Application to Health Plan DM Data Savings results can vary considerably depending on identification, method, and assumptions. In order to understand specific savings results, a great deal of information and disclosure is required. More than one assumption can be varied: we did not test multi-variate results. We continue to test other assumptions: one of these is the "no requalification" assumption. Many purchasers want to know the results by disease. 40 9: Wellness Programs • Wellness Programs are the fastest-growing area in employer-sponsored interventions in the US. • Common program components are: Assessment through HRA; Interventions such as DM, nutrition coaching, substance abuse counseling, health information, etc.; Distribution channel (coaches/electronic/paper, etc.); Biometric testing/collection; Integration with other programs (DM, case management, disability management etc.); Outcomes measurement. 41 9: Wellness Program Measures hronic Disease History fluenza/ Pneumonia

| 9: V | Vellness Program Value | |
|---------------|--|-------------------------------|
| | | |
| | Regression analysis of the relation factors and claims costs (Female I | ship between lodel example |
| | ractors and claims costs (Female 1 | - Iouci cxampic |
| i. | Risk Factor Coefficient Risk Factor 1. Intercept \$ 190 9. Pregnancy state | Coefficient /plan \$ 590 |
| SOLUCIA, INC. | 2. History of COPD,CHF, CHD, PCD or Stroke 10.55310. Body Mass Inc. | x 118 |
| Š. | 3. Sigmoidoscopy within the last 5 years? 2,045 min. per day | ity exercise- (46) |
| | 12. In the last mo 4. Influenza in last 12 months? 1,176angered? 5. Never diagnosed any of 27 major conditions? (1,220)jskin check | 1,632 |
| | 6. TIA , HA, Angina, Breast Cancer, 14. High intensity | ctivities? (hrs |
| | 2,589[ser week) 7. Pneumonia 1,11815. Servings of gr | |
| | 8. Currently/planning hormone 16. Rate confiden replacement therapy? 999smoke when blue | to not (294) |
| | 43 | |
| | 43 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Conc | clusion | |
| COIL | .1031011 | |
| | | |
| | An important and growing area for h | ealth payers, |
| | irrespective of system. | , , , |
| | An opportunity for actuaries, if we w | nt to take it |
| <u>.</u> | All opportunity for actualles, if we w | int to take it. |
| Z | | |
| Ă, | | |
| SOLUCIA, INC. | | |
| | | |
| | | |
| | | |
| | | |
| | 44 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Ques | stions? | |
| | | |
| | THANK YOU FOR Y | |
| | PARTICIPATIO | |
| | | |
| | Ian Duncan, FSA FIA FCIA MAAA Solucia Ltd. | |
| NC | #4, 16 Cadogan Gardens | |
| SOLUCIA, INC. | London SW3 2RS US: (001) 860-614-3295 | |
| CIA | UK: 07726 283 331 | |
| 070 | iduncan@soluciaconsulting.com www.soluciaconsulting.com | |
| | | |
| | | |
| | | |
| | 45 | |